To our knowledge, three studies have reported on erythroid response to lenalidomide with or without EPO in transfusion-dependent, ESA-refractory/ineligible patients with non-del(5q) lower-risk MDS (Table 3) [69–71]. This evidence concerns the gene EPO and myelodysplastic syndrome.